1. Introduction {#sec1}
===============

Several studies have shown that reducing myocardial ischemia with coronary artery intervention improves both quality of life and clinical outcomes \[[@B1], [@B2]\]. The fractional flow reserve (FFR) is a hyperemic pressure-derived ratio that is considered the reference standard method for evaluating the functional severity of coronary artery stenosis based on substantial clinical outcome data \[[@B3]--[@B5]\]. The instantaneous wave-free ratio (iFR) is a nonhyperemic pressure-derived ratio; randomized controlled trials have demonstrated that the iFR-guided revascularization is not inferior to FFR-guided revascularization \[[@B6], [@B7]\].

The FFR and iFR correlate well and are similar coronary functional indexes, although they differ in some respects; specifically, FFR is calculated by the pressure ratio during the entire cardiac cycle period under hyperemia, while the iFR is calculated by the pressure ratio during the diastolic cardiac cycle under resting conditions. The rate pressure product (RPP) is calculated as systolic blood pressure multiplied by the heart rate, which is an index of myocardial metabolism that is closely correlated with myocardial hemodynamics \[[@B8]\]. Previous reports suggested that the coronary blood flow at resting condition was easily affected by the fluctuation in blood pressure or heart rate, but the coronary blood flow under hyperemia was not \[[@B9], [@B10]\]. No studies, to date, have reported on the effects of the RPP on the relationship between the FFR and iFR. Therefore, the aim of this study was to evaluate the effects of the RPP on the FFR and iFR relationship. We also determined how the diagnostic performance of the iFR is affected by the RPP when FFR is set as the gold standard.

2. Materials and Methods {#sec2}
========================

2.1. Patient Population {#sec2.1}
-----------------------

In this study, we enrolled patients who had undergone clinically indicated invasive coronary angiography as well as both the iFR and FFR examinations between 2012 and 2017. Because we examined how the RPP affect the relationship between the FFR and iFR, we limited our analysis to patients who had undergone blood pressure and heart rate measurements just prior to the iFR and FFR evaluations. It is difficult to accurately assess the RPP in patients with atrial fibrillation. We, therefore, excluded patients who had had atrial fibrillation. Hemodialysis patients characteristically exhibit specific hemodynamic conditions; therefore, such patients were excluded. We also excluded patients with lesions in the left main trunk and those with bypass grafts. Finally, we excluded patients with ST segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or New York Heart Association class IV heart failure. We included the patients with unstable angina pectoris, but the stenoses interrogated were the nonculprit lesions.

2.2. Measurement of Rate Pressure Products {#sec2.2}
------------------------------------------

The RPP was defined as the systolic blood pressure multiplied by the heart rate. Blood pressure and heart rate measurements taken just prior to the iFR measurement were used for the calculation. Blood pressure data were extracted from hemodynamic records taken during cardiac catheterization and had been measured using either invasive monitoring of the arterial catheter or a sphygmomanometer. Heart rate was recorded from the electrocardiography monitor or the oxygen saturation monitor. We divided lesions into two groups based on whether the RPP just prior to the iFR measurement for each lesion was greater or lesser than the median RPP; thus, patients in the low- and high-RPP groups had lesions with the RPP \<8512 and ≥8512, respectively. Lesion characteristics were compared between the groups as were the correlations and biases between the FFR and iFR.

2.3. Coronary Angiography, Quantitative Coronary Angiography, and Echocardiography {#sec2.3}
----------------------------------------------------------------------------------

Coronary angiography was performed according to standard clinical methods via the radial or femoral arterial approach. Quantitative coronary angiography (QCA) was performed by an independent physician using a computer-assisted automated edge detection algorithm \[[@B11]\]; the physician was blinded to the results of the iFR and FFR. The external diameter of the contrast-filled catheter (5-Fr or 6-Fr) was used as the calibration standard. The percentage of the stenosis diameter during end-diastole was measured using the worst-view trace. Echocardiography measurements were performed according to American Society of Echocardiography guidelines by an independent physician who was blinded to the results of the FFR and iFR. The left ventricular mass index and *E*/*e*ʹ ratio were added to the analysis.

2.4. Standard iFR and FFR Measurements {#sec2.4}
--------------------------------------

Both the iFR and FFR examinations were performed using either diagnostic or interventional guiding catheters. After administering an intracoronary bolus of nitroglycerin, a coronary pressure wire (Prime Wire Prestige; Philips Volcano Corporation, San Diego, CA, USA) was calibrated outside of the body and advanced such that the sensor was positioned at the tip of the guiding catheter where the two pressures were equalized and recorded. After completion of the pressure equalization at the tip of the guide catheter, the guidewire was advanced to a point distal to the stenosis. First, the iFR was directly and automatically measured online using the Volcano Core system (Philips Volcano). Second, the FFR was measured during maximal hyperemia. Hyperemia in the target coronary artery was achieved either with an intracoronary bolus injection of 8--12 mg papaverine or with continuous intravenous administration of adenosine at 150 *µ*g/kg/min. At the end of each measurement, the pressure sensor was retracted to the tip of the guide catheter to avoid pressure drift.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Continuous data were expressed as means ± standard deviations. Categorical data were expressed as absolute values and percentages. The comparisons were made using Welch\'s *t*-test for normally distributed continuous variables, the Mann--Whitney *U* test for nonnormally distributed continuous variables, and Pearson\'s chi-squared test for categorical variables. Correlations between parameters were tested using Pearson\'s correlation coefficients. Fisher\'s r-to-z transformation was used to assess the significance of the difference between two correlation coefficients. Bland--Altman analysis was conducted to evaluate the bias and limits of agreement between each parameter. ROC curves were used to evaluate the diagnostic performance of the iFR when identifying a positive FFR measurement using the area under the curve (AUC). Multivariable regression analysis was performed to determine predictors of the FFR and iFR. Variables were included in the multivariable model if they reached *p* \< 0.20 after univariable regression analysis. *p* values \<0.05 were considered to indicate statistical significance. Statistical analyses were performed using JMP statistical software (JMP Pro 14.0; SAS Institute Inc., Cary, NC, USA).

2.6. Compliance with Ethical Standards {#sec2.6}
--------------------------------------

The study protocol was based on the regulations of the hospital\'s ethics committee. All participating patients provided written informed consent. The study was conducted according to the principles of the 1975 Declaration of Helsinki.

3. Results {#sec3}
==========

We enrolled 195 consecutive patients with 259 lesions in this study. The study patient characteristics are shown in [Table 1](#tab1){ref-type="table"}. The mean patient age was 68.8 ± 10.4 years; 57.9% of patients had diabetes mellitus, 72.3% had hypertension, and 67.2% had hypercholesterolemia. The mean left ventricular ejection fraction was 51.3%, and the mean glomerular filtration rate was 60.4 mL/min/1.73 m^2^.

The median RPP was 8512 (interquartile range: 7200, 10220) (Supplemental [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}). A total of 129 (49.8%) lesions were classified as belonging to the low-RPP group (mean RPP: 6981 ± 1149) and 130 (50.2%) to the high-RPP group (mean RPP: 10391 ± 1603) according to the median RPP. Lesion characteristics of the low-RPP and high-RPP groups are shown in [Table 2](#tab2){ref-type="table"}.

In comparison with the lesions in the low-RPP group, the lesions in the high-RPP group tended to be in older patients, females, nonsmokers, and patients with a history of myocardial infarction. The E/e\' ratio in the high-RPP group was higher than that in the low-RPP group (14.1 ± 6.4 vs. 12.5 ± 4.5, respectively, *p*=0.045). No significant difference was observed in the QCA parameters.

The correlation between the FFR and iFR in the high-RPP group was significantly higher than that of the low-RPP group (Pearson\'s correlation: *r* = 0.82 vs. *r* = 0.63, respectively, *z* = 3.3, *p*=0.001, [Figure 1](#fig1){ref-type="fig"}).

According to Bland--Altman analysis, the bias between the FFR and iFR in the high-RPP group was 0.058 (95% confidence interval (CI): 0.042--0.074) and that of the low-RPP group was 0.097 (95% CI: 0.079--0.115) ([Figure 2](#fig2){ref-type="fig"}).

The best cutoff value of the iFR for predicting an FFR of 0.80 was 0.90 for all lesions (AUC 0.79, sensitivity 0.74, specificity 0.67, and *p* \< 0.0001), with 0.93 for the low-RPP group (AUC 0.83, sensitivity 0.87, specificity 0.62, and *p* \< 0.0001), and 0.82 for the high-RPP group (AUC 0.79, sensitivity 0.57, specificity 0.93, and *p* \< 0.0001) ([Figure 3](#fig3){ref-type="fig"}) (Supplemental [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}).

Using the current iFR cutoff values of ≤0.89, 26.4% of lesions in the low-RPP group would be underestimated, while 16.9% of lesions in the high-RPP group would be overestimated (Supplemental [Figure 3](#supplementary-material-1){ref-type="supplementary-material"}).

Though there was no significant correlation between the RPP and FFR, the RPP and iFR showed a weak but significant inverse correlation (Pearson\'s correlation: *r* = 0.14; *p*=0.029) ([Figure 4](#fig4){ref-type="fig"}).

[Table 3](#tab3){ref-type="table"} shows the variables which were associated with the iFR or FFR. In the univariable analysis, female sex (*p*=0.11) and the presence of diabetes mellitus (*p*=0.04) were potential predictors of FFR. The age (*p*=0.02), presence of diabetes mellitus (*p* \< 0.0001), prior revascularization (*p*=0.05), left ventricular mass index (*p*=0.19), E/e\' (*p*=0.01), glomerular filtration rate (*p*=0.01), and RPP (*p*=0.04) were potential predictors of the iFR. Presence of diabetes mellitus was the independent predictor of FFR in multivariable analysis (*p*=0.04; *β* = 0.13). The presence of diabetes mellitus (*p*=0.002; *β* = 0.23) and the RPP (*p*=0.04; *β* = -0.15) were independent predictors of the iFR.

The best cutoff value of the RPP to predict discordance of the iFR ≤ 0.89 and FFR \> 0.8 was 10950 and 6572 for discordance of the iFR \> 0.89 and FFR ≤ 0.8 ([Figure 5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

The RPP is an index that reflects myocardial metabolism and greatly affects the hemodynamics of the heart \[[@B8]\], suggesting that coronary artery pressure-derived indexes could be influenced by the RPP. No previous study has reported the influence of the RPP on the relationship between the FFR and iFR.

The primary findings in the present study were as follows: (1) the correlation between the FFR and iFR in the high-RPP group was higher than that of the low-RPP group; (2) the best cutoff value of the iFR for predicting an FFR of 0.8 was 0.90 for all lesions, 0.93 for the low-RPP group, and 0.82 for the high-RPP group; and (3) the iFR and RPP showed a weak but a statistically significant negative correlation. No similar result was found for the FFR and RPP. Moreover, multivariable analysis revealed that the RPP was independently associated with the iFR.

The reason for the higher correlation between the iFR and FFR in the high-RPP group might be that the oxygen consumption of the myocardium was increased, resulting in increased coronary blood flow to maintain the oxygen supply in the high-RPP group. If one simply considers the amount of blood flow in the coronary arteries, coronary blood flow under resting conditions in the high-RPP group may increase and be closer to that of the hyperemic condition. Hence, the correlation between the iFR and FFR in the high-RPP group is likely to be increased. The question remains as to whether FFR would be affected in a high-RPP environment. A previous study reported that coronary blood flow under hyperemia did not correlate with the RPP, while coronary blood flow under resting conditions had a significant positive correlation with the RPP \[[@B9]\]. Similarly, although we did not observe a significant correlation between the RPP and FFR, the RPP and iFR showed a weak but a significant negative correlation. de Bruyne et al. reported that the FFR was almost independent of hemodynamic changes including heart rate and blood pressure \[[@B10]\]. Kolli et al. reported that fluctuations in the heart rate had no significant influence on the measured values of FFR in a porcine model \[[@B12]\]. By contrast, a study reported that hyperemic coronary flow decreased, and resting coronary flow was maintained in an environment where coronary circulation compensated for microvascular resistance \[[@B13]\]. However, if the FFR is measured when the coronary microcirculation is optimally dilated using the correct method and correct hyperemic agent, the FFR value might not be affected by the RPP value.

As regards the patient characteristics in our study, a total of 58% patients had diabetes mellitus, which is an important covariate for microvascular dysfunction. There are also numerous reports which have suggested that the higher left ventricular mass index and higher *E*/*e*′ ratio are associated with microvascular dysfunction \[[@B14], [@B15]\]. When adding the variables including the presence of diabetes mellitus, left ventricular mass index, and E/e\' ratio to the multivariable analysis to clarify the predictor of the iFR, the RPP was independently associated with the iFR. These data suggest that the iFR might be affected by the RPP regardless of microvascular dysfunction.

In this study, the best cutoff value of the iFR for predicting an FFR of 0.8 was 0.90 for all lesions. This value agrees with previously reported values. The best cutoff value for the low-RPP group was 0.93, higher than the standard predictive value of the iFR. The best cutoff value for the high-RPP group was 0.82, lower than the standard predictive value of the iFR. When using the corrected iFR cutoff values of ≤0.93 for the low-RPP group and ≤0.82 for the high-RPP group, a total of 23 (17.8%) lesions should be reclassified as "ischemic" in the low-RPP group and a total of 16 (12.3 %) lesions should be reclassified as "nonischemic" in the high-RPP group.

The FFR has hemodynamic independence through dilating and maximizing the coronary microcirculation in hyperemia. The iFR value is sensitive to the RPP fluctuations, while the FFR is less susceptible to the RPP fluctuations. Jain et al. reported that mental stress increased the RPP \[[@B16]\]. In this study, the stressful condition may have the greatest effect on the RPP value because the comorbidity of hypertension did not change between the high-RPP group and the low-RPP group. When examining the iFR, it may also be necessary to make this as stress-free as possible. Then, the difference between low- vs. high-RPP is more likely associated with patient hemodynamics at the time of physiologic assessment, further suggesting the stability of hyperemic measurements as opposed to resting measurements. Even if the iFR is positive, there is a possibility of false positive if the RPP is 10950 or more at the time of the iFR measurement. Further, if the iFR is negative, there is a possibility of false negative if the RPP is 6572 or less at the time of the iFR measurement. Additional studies with a prospective study design and larger numbers of patients are necessary to validate the relation between the rate pressure products and iFR and FFR.

There are several limitations to this study. First, this was a retrospective observational cohort study conducted at a single center, and the number of study patients was relatively small. Second, there were no data on the changes in the iFR values at rest and during exercise in the same patients, and there were also no data on the clinical endpoints. Third, the prevalence of diabetes mellitus and hypertension was higher than those of previous studies. These comorbidities induce structural changes in the myocardium and reduce coronary capacity, possibly influencing the relationship between the iFR and FFR. Fourth, analyses vary depending on which indicator is considered the gold standard. There is, however, abundant evidence in favor of using the FFR, and it is currently the most reliable index recommended in the guidelines. Furthermore, the FFR has customarily been the benchmark for evaluating other nonhyperemic indices. Fifth, there are no data on medication (i.e., calcium-channel blocker and beta-blocker), which might influence the results.

5. Conclusion {#sec5}
=============

Rate pressure products may affect the relationship between the FFR and iFR. Setting FFR as the reference gold standard, the iFR may underestimate the functionality of ischemia in the low-RPP group and overestimate it in the high-RPP group.
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###### 

Supplemental Figure 1: distribution of the rate pressure products. Supplemental Figure 2: diagnostic ability of the iFR in the high-RPP and low-RPP groups with respect to the FFR. Supplemental Figure 3: correlation between the FFR and iFR in the high-RPP and low-RPP groups.

###### 

Click here for additional data file.

![Scatter plots of the FFR and iFR in the low-RPP group (a) and the high-RPP group (b). RPP, rate pressure product; iFR, instantaneous wave-free ratio; FFR, fractional flow reserve.](JITC2020-6230153.001){#fig1}

![Bland--Altman plot comparing the FFR and iFR in the low-RPP group (a) and the high-RPP group (b). RPP, rate pressure products; iFR, instantaneous wave-free ratio; FFR, fractional flow reserve.](JITC2020-6230153.002){#fig2}

![Receiver-operating characteristic curves of the iFR values for an FFR of 0.8 in all lesions (a), the low-RPP group (b), and high-RPP group (c). RPP, rate pressure products; AUC, area under the curve.](JITC2020-6230153.003){#fig3}

![Scatter plots comparing the RPP with the FFR (a) and iFR (b). RPP, rate pressure products; iFR, instantaneous wave-free ratio; FFR, fractional flow reserve.](JITC2020-6230153.004){#fig4}

![The best cutoff value of rate pressure products to predict discordance of the iFR ≤ 0.89 and FFR \> 0.8 (a) and discordance of the iFR \> 0.89 and FFR ≤ 0.8 (b). RPP, rate pressure products; iFR, instantaneous wave-free ratio; FFR, fractional flow reserve.](JITC2020-6230153.005){#fig5}

###### 

Patients\' characteristics.

  Patients\' variables                            *n* = 195
  ----------------------------------------------- -------------
  Age                                             68.8 ± 10.4
  Men                                             45 (23.1%)
  Body mass index (kg/m^2^)                       23.9 ± 3.5
  Diabetes mellitus                               113 (57.9%)
  Hypertension                                    141 (72.3%)
  Hyperlipidemia                                  131 (67.2%)
  Smoking                                         69 (35.4%)
  Prior myocardial infarction                     58 (29.7%)
  Revascularization                               105 (53.8%)
  Left ventricular ejection fraction (%)          51.3 ± 9.7
  Chronic kidney disease (\>stage II)             102 (52.3%)
  Glomerular filtration rate (mL/min/1.73 m^2^)   60.4 ± 16.4

^*∗*^Data are expressed as mean ± standard deviation or as number (percentage).

###### 

Lesion characteristics divided by the median of the rate pressure products.

                                        Low-RPP group (*n* = 129)   High-RPP group (*n* = 130)   *p* value
  ------------------------------------- --------------------------- ---------------------------- -----------
  Age                                   67.8 ± 11.4                 70.8 ± 9.0                   0.02
  Female                                23 (17.8%)                  40 (30.8%)                   0.02
  Body mass index (kg/m^2^)             23.7 ± 3.8                  23.9 ± 3.6                   0.74
  Diabetes mellitus                     68 (52.7%)                  83 (63.9%)                   0.08
  Hypertension                          92 (71.3%)                  98 (75.4%)                   0.48
  Hyperlipidemia                        95 (73.6%)                  83 (63.9%)                   0.11
  Smoking                               59 (45.7%)                  37 (28.5%)                   0.005
  Prior myocardial infarction           33 (25.6%)                  49 (37.7%)                   0.045
  Revascularization                     78 (60.5%)                  68 (52.3%)                   0.21
  LVEF (%)                              49.9 ± 10.6                 51.9 ± 8.7                   0.10
  LVMI (g/m^2^)                         98.7 ± 29.8                 91.5 ± 30.6                  0.11
  *E*/*e*′                              12.5 ± 4.5                  14.1 ± 6.4                   0.048
  Chronic kidney disease (\>stage II)   69 (53.5%)                  71 (54.6%)                   0.9
  GFR (mL/min/1.73 m^2^)                60.9 ± 17.1                 58.0 ± 17.2                  0.18
  Percent diameter stenosis             63.6 ± 17.4                 63.0 ± 18.3                  0.77
  Left anterior descending artery       78 (60.5%)                  69 (53.1%)                   0.26
  Circumflex artery                     24 (18.6%)                  30 (23.1%)                   0.44
  Right coronary artery                 27 (20.9%)                  31 (23.9%)                   0.66
  FFR                                   0.77 ± 0.11                 0.78 ± 0.12                  0.51
  iFR                                   0.87 ± 0.13                 0.84 ± 0.16                  0.09
  Percent diameter stenosis             64 ± 17                     63 ± 18                      0.77
  Lesion diameter (mm)                  17.7 ± 6.9                  18.5 ± 6.9                   0.32
  Reference diameter (mm)               2.7 ± 0.5                   2.6 ± 0.5                    0.06
  Diffuse/tandem lesion                 37 (28.7%)                  37 (28.7%)                   0.89
  Rate pressure products                6981 ± 123                  10392 ± 122                  \<0.0001
  Systolic blood pressure (mmHg)        111 ± 19.0                  138 ± 19.9                   \<0.0001
  Heart rate (beats/minute)             63.3 ± 8.4                  76.0 ± 12.2                  \<0.0001

RPP, rate pressure products; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; GFR, glomerular filtration rate; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio. ^*∗*^Data are expressed as mean ± standard deviation or as number (percentage).

###### 

The variables associated with the FFR and iFR.

                                FFR      iFR                                             
  ----------------------------- -------- ------ ------ ------ ------- ---------- ------- -------
  Age                           0.04     0.52                 −0.15   0.02       −0.01   0.87
  Female                        −0.1     0.11   −0.1   0.12   0.03    0.59                
  Body mass index               −0.07    0.25                 0.02    0.77                
  Diabetes mellitus             0.13     0.04   0.13   0.04   0.24    \<0.0001   0.23    0.002
  Hypertension                  0.005    0.94                 0.02    0.7                 
  Dyslipidemia                  0.03     0.61                 −0.07   0.24                
  Smoking                       0.07     0.28                 −0.05   0.47                
  Prior myocardial infarction   −0.04    0.50                 0.02    0.77                
  Prior revascularization       −0.07    0.29                 −0.12   0.05       −0.1    0.21
  LVEF                          0.02     0.79                 0.04    0.52                
  LVMI                          −0.04    0.60                 −0.1    0.19       −0.06   0.49
  *E*/*e*′                      −0.07    0.35                 −0.18   0.01       −0.05   0.58
  GFR                           0.08     0.21                 0.16    0.01       0.13    0.13
  Rate pressure products        −0.001   0.99                 −0.14   0.03       −0.15   0.04

LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; GFR, glomerular filtration rate; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio.
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